Morgan Stanley Werewolf Therapeutics, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 19,252 shares of HOWL stock, worth $18,096. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,252

Previous 27,200 29.22%

Holding current value

$18,096

Previous $29,000 31.03%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.05 - $2.19 $8,345 - $17,406	-7,948 Reduced 29.22%	19,252 $38,000
Q2 2025 Aug 15, 2025	SELL	$0.63 - $1.42 $50,795 - $114,490	-80,627 Reduced 74.77%	27,200 $29,000
Q1 2025 May 15, 2025	SELL	$0.97 - $1.68 $29,405 - $50,929	-30,315 Reduced 21.94%	107,827 $104,000
Q4 2024 Feb 14, 2025	BUY	$1.48 - $3.63 $28,270 - $69,340	19,102 Added 16.05%	138,142 $204,000
Q3 2024 May 14, 2025	BUY	$1.71 - $2.95 $119,747 - $206,582	70,028 Added 142.88%	119,040 $252,000

Q3 2024 Nov 14, 2024	BUY	$1.71 - $2.95 $119,747 - $206,582	70,028 Added 142.88%	119,040 $252,000
Q2 2024 May 14, 2025	SELL	$2.34 - $6.75 $208,564 - $601,627	-89,130 Reduced 64.52%	49,012 $119,000
Q2 2024 Oct 17, 2024	BUY	$2.34 - $6.75 $66,533 - $191,922	28,433 Added 138.17%	49,012 $119,000
Q2 2024 Aug 14, 2024	BUY	$2.34 - $6.75 $66,533 - $191,922	28,433 Added 138.17%	49,012 $119,000
Q1 2024 Oct 17, 2024	SELL	$3.92 - $7.91 $111,457 - $224,905	-28,433 Reduced 58.01%	20,579 $133,000
Q1 2024 Aug 16, 2024	BUY	$3.92 - $7.91 $78,317 - $158,033	19,979 Added 3329.83%	20,579 $133,000
Q1 2024 May 15, 2024	BUY	$3.92 - $7.91 $78,317 - $158,033	19,979 Added 3329.83%	20,579 $133,000
Q4 2023 Aug 16, 2024	SELL	$1.78 - $4.15 $86,173 - $200,909	-48,412 Reduced 98.78%	600 $2,000
Q4 2023 Feb 13, 2024	SELL	$1.78 - $4.15 $3,382 - $7,885	-1,900 Reduced 76.0%	600 $2,000
Q1 2023 May 15, 2023	SELL	$1.98 - $4.3 $23 - $51	-12 Reduced 0.48%	2,500 $6,000
Q4 2022 Feb 14, 2023	SELL	$1.53 - $4.73 $12,201 - $37,721	-7,975 Reduced 76.05%	2,512 $5,000
Q3 2022 Nov 14, 2022	SELL	$4.14 - $7.42 $48,847 - $87,548	-11,799 Reduced 52.94%	10,487 $47,000
Q2 2022 Oct 27, 2022	BUY	$3.43 - $5.98 $50,270 - $87,642	14,656 Added 192.08%	22,286 $91,000
Q2 2022 Aug 15, 2022	BUY	$3.43 - $5.98 $50,270 - $87,642	14,656 Added 192.08%	22,286 $91,000
Q1 2022 Oct 27, 2022	SELL	$3.71 - $12.22 $54,373 - $179,096	-14,656 Reduced 65.76%	7,630 $33,000
Q1 2022 May 13, 2022	SELL	$3.71 - $12.22 $1,606 - $5,291	-433 Reduced 5.37%	7,630 $33,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.65 $75,182 - $115,589	6,549 Added 432.56%	8,063 $96,000
Q3 2021 Nov 15, 2021	BUY	$13.89 - $20.31 $21,029 - $30,749	1,514 New	1,514 $26,000

Others Institutions Holding HOWL

# of Institutions

Shares Held

22.7M

Call Options Held

Put Options Held

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $27.8M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account